SEARCH

SEARCH BY CITATION

References

  • 1
    You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ, Halperin JL, Lip GYH. Antithrombotic therapy for atrial fibrillation: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e531Se575S.
  • 2
    Wells G, Coyle D, Cameron C, Steiner S, Coyle K, Kelly S, Tang A, Healey J, Hsieh S-C, Berkom JV. Safety, effectiveness, and cost-effectiveness of new oral anticoagulants compared with warfarin in preventing stroke and other cardiovascular events in patients with atrial fibrillation. Canadian Agency for Drugs and Technologies in Health (CADTH): Therapeutic Review 2012; Available: http://cadth.ca/media/pdf/NOAC_Therapeutic_Review_final_report.pdf . Accessed 28 January 2013.
  • 3
    Whitlock RP, Sun JC, Fremes SE, Rubens FD, Teoh KH. Antithrombotic and thrombolytic therapy for valvular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e576S600S.
  • 4
    Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (2 Suppl): e419S94S.
  • 5
    Fox BD, Kahn SR, Langleben D, Eisenberg MJ, Shimony A. Efficacy and safety of novel oral anticoagulants for treatment of acute venous thromboembolism: direct and adjusted indirect meta-analysis of randomised controlled trials. BMJ 2012 Nov 13; 345: e7498.
  • 6
    Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e44S88S.
  • 7
    Gadisseur APA, Breukink-Engbers WGM, Van Der Meer FJM, Van Den Besselaar AMH, Sturk A, Rosendaal FR. Comparison of the quality of oral anticoagulant therapy through patient self-management and management by specialized anticoagulation clinics in the Netherlands: a randomized clinical trial. Arch Intern Med 2003; 163: 263946.
  • 8
    Pernod G, Labarère J, Yver J, Satger B, Allenet B, Berremili T, Fontaine M, Franco G, Bosson JL. EDUC'AVK: reduction of oral anticoagulant-related adverse events after patient education: a prospective multicenter open randomized study. J Gen Intern Med 2008; 23 (9): 14416.
  • 9
    Léger S, Allenet B, Pichot O, Figari G, Calop J, Carpentier P, Bosson JL. Impact d'un programme d'éducation thérapeutique sur les attitudes de prévention vis-à-vis du risque iatrogène: étude pilote contrôlée visant les patients sous anticoagulants oraux pour maladie thromboembolique veineuse. J Mal Vasc 2004; 29: 1528.
  • 10
    Laporte S, Quenet S, Buchmuller-Cordier A, Reynaud J, Tardy-Poncet B, Thirion C, Decousus H, Mismetti P. Compliance and stability of INR of two oral anticoagulants with different half-lives: a randomised trial. Thromb Haemost 2003; 89: 45867.
  • 11
    Clark CM, Bayley EW. Evaluation of the use of programmed instruction for patients maintained on warfarin therapy. Am J Public Health 1972; 62: 11359.
  • 12
    Gadisseur APA, Kaptein AA, Breukink-Engbers WGM, Van Der Meer FJM, Rosendaal FR. Patient self-management of oral anticoagulant care vs. management by specialized anticoagulation clinics: positive effects on quality of life. J Thromb Haemost 2004; 2: 58491.
  • 13
    Holbrook A, Schulman S, Witt DM, Vandvik PO, Fish J, Kovacs MJ, Svensson PJ, Veenstra DL, Crowther M, Guyatt GH. Evidence-based management of anticoagulant therapy: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e152S84S.
  • 14
    Palareti G, Legnani C, Guazzaloca G, Lelia V, Cosmi B, Lunghi B, Marchetti G, Poli D, Pengo V, the ad hoc study group of the Italian Federation of Anticoagulation C. Risks factors for highly unstable response to oral anticoagulation: a case–control study. Br J Haematol 2005; 129: 728.
  • 15
    Tang EOYL, Lai CSM, Lee KKC, Wong RSM, Cheng G, Chan TYK. Relationship between patients' warfarin knowledge and anticoagulation control. Ann Pharmacother 2003; 37: 349.
  • 16
    Kagansky N, Knobler H, Rimon E, Ozer Z, Levy S. Safety of anticoagulation therapy in well-informed older patients. Arch Intern Med 2004; 164: 204450.
  • 17
    Wofford J, Wells M, Singh S. Best strategies for patient education about anticoagulation with warfarin: a systematic review. BMC Health Serv Res 2008; 8: 407.
  • 18
    Samsa GP, Matchar DB. Relationship between test frequency and outcomes of anticoagulation: a literature review and commentary with implications for the design of randomized trials of patient self-management. J Thromb Thrombolysis 2000; 9: 28392.
  • 19
    Group CCaCR. Data extraction template for Cochrane reviews. Cochrane Collaboration, 2009; 1.3.0.
  • 20
    Machtinger EL, Wang F, Chen L-L, Rodriguez M, Wu S, Schillinger D. A visual medication schedule to improve anticoagulation control: a randomized, controlled trial. Jt Comm J Qual Patient Saf 2007; 33: 62535.
  • 21
    Rosendaal FR, Cannegieter SC, van der Meer FJ, Briet E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 2369.
  • 22
    Higgins J, Green S. Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2. The Cochrane Collaboration, 2009; www.cochrane-handbook.org. Accessed 5 June 2009.
  • 23
    Guyatt GH, Oxman AD, Kunz R, Vist GE, Falck-Ytter Y, Schünemann HJ. What is ‘quality of evidence’ and why is it important to clinicians? BMJ 2008; 336: 9958.
  • 24
    Brozek J, Oxman A, Schünemann H. GRADEpro [Computer program]. Version 3.2 for Windows. 2008.
  • 25
    Review Manager (RevMan) [Computer Program]. Version 5.1. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2011.
  • 26
    Moher D, Liberati A, Tetzlaff J, Altman D. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009; 6: e1000097.
  • 27
    Khan TI, Kamali F, Kesteven P, Avery P, Wynne H. The value of education and self-monitoring in the management of warfarin therapy in older patients with unstable control of anticoagulation. Br J Haematol 2004; 126: 55764.
  • 28
    Mazor KM, Baril J, Dugan E, Spencer F, Burgwinkle P, Gurwitz JH. Patient education about anticoagulant medication: is narrative evidence or statistical evidence more effective? Patient Educ Couns 2007; 69: 14557.
  • 29
    The Joint Commission US. National patient safety goals. 2012, http://www.jointcommission.org/assets/1/6/NPSG_Chapter_Jan2012_HAP.pdf. Accessed 20 February 2012.
  • 30
    Cousins D. Risk assessment of anticoagulation therapy. National Patient Safety Agency, 2006, http://www.npsa.nhs.uk/patientsafety/alerts-and-directives/alerts/anticoagulant. Accessed 20 February 2012.
  • 31
    Budnitz DS, Lovegrove MC, Shehab N, Richards CL. Emergency hospitalizations for adverse drug events in older Americans. N Engl J Med 2011; 365: 200212.
  • 32
    Anticoagulants the Leading Reported Drug Risk in 2011. Institute for Safe Medication Practices, 2011 Quarters 3-4. QuarterWatch: Monitoring FDA MedWatch Reports. Available: www.ismp.org/quarterwatch/pdfs/2011Q4.pdf. Accessed 28 January 2013.